Integrase strand transfer inhibitor-associated diabetes mellitus: A case report
Authors:
- 12 October 2016
- journal article
- case report
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 28 (6) , 626-628
Abstract
Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavirenz to abacavir, lamivudine, and raltegravir. Hemoglobin A1C normalized without further need for exogenous insulin after raltegravir was switched back to efavirenz. In this case report, we will review a possible mechanism for INSTI-induced hyperglycemia and/or diabetes mellitus.Keywords
This publication has 9 references indexed in Scilit:
- Insulin Modulates the Na+/Mg2+ Exchanger SLC41A1 and Influences Mg2+ Efflux from Intracellular Stores in Transgenic HEK293 CellsThe Journal of Nutrition, 2015
- Magnesium and type 2 diabetesWorld Journal of Diabetes, 2015
- Serum ionized magnesium in diabetic older personsMetabolism, 2014
- Hypomagnesemia in Patients with Type 2 DiabetesClinical Journal of the American Society of Nephrology, 2007
- Three-dimensional Structural Interactions of Insulin and Its ReceptorJournal of Biological Chemistry, 2003
- Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymesProceedings of the National Academy of Sciences, 2002
- Structural Determinants for HIV-1 Integrase Inhibition by β-Diketo AcidsJournal of Biological Chemistry, 2002
- An Essential Interaction between Distinct Domains of HIV-1 Integrase Mediates Assembly of the Active MultimerJournal of Biological Chemistry, 1995
- Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitroJournal of Virology, 1992